Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy 2022-09-20 19:25
New treatment for rare cancer cholangiocarcinoma approved in Australia 2022-09-15 21:00
Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance 2022-09-15 17:07
J INTS BIO, poster presentation of further preclinical data of its Novel Oral 4th Generation EGFR-TKI 'JIN-A02' at the 2022 European Society for Medical Oncology Congress in Paris, France (ESMO 2022) 2022-09-15 14:12
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome 2022-09-13 20:00
First and only TIGIT/TGF-β dual-targeting antibody fusion protein of Akeso demonstrated promise in preclinical results published at ESMO 2022-09-13 14:02
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 2022-09-10 21:00
Redbud raises $10M in series A round as CRO focusing on science-driven clinical development 2022-09-10 05:13
111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company 2022-09-09 17:53
Antengene to Present at Upcoming Industry Conferences 2022-09-09 14:43
Lianhua Products Designated as Epidemic Prevention Supplies : 2022 CIFTIS 2022-09-07 20:15
GenFleet Therapeutics to Present Data from Phase I Trial of GFH018 Monotherapy at the 2022 European Society for Medical Oncology Annual Meeting 2022-09-07 19:00
Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China 2022-09-06 15:20
Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO 2022-09-05 22:49
Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Breast Cancer at 2022 ESMO 2022-09-05 22:39
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. announce a research collaboration in the field of anti-infectives 2022-09-05 16:00
Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue 2022-09-05 13:09
Tamas Oravecz Ph.D. named SVP, CSO of the U.S. of Simcere Pharmaceutical Group 2022-09-05 13:08
Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China 2022-09-02 19:00
Bridge Biotherapeutics Presented Non-clinical Study Results for 2 IPF Candidates at the IPF Summit 2022 2022-09-02 09:41
1 68 69 70 71 72 165